NCT02626026View on ClinicalTrials.gov

Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA)

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

January 26, 2016

Primary Completion Date

September 1, 2016

Study Completion Date

September 1, 2016

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Tirabrutinib

Capsules administered orally.

DRUG

Placebo

Capsules administered orally.

Trial Locations (9)

16635

Altoona Center for Clinical Research, Duncansville

19610

Clinical Research Center of Reading, LLC, Wyomissing

32804

Omega Research Consultants, LLC, Orlando

33126

SeaView Research, Inc., Miami

34292

Lovelace Scientific Resources, Inc., Venice

42701

Center for Arthritis & Osteoporosis, Elizabethtown

48910

Justus J. Fiechtner, M.D., P.C., Lansing

78232

Arthritis & Osteoporosis Center of South Texas, San Antonio

95817

UC Davis Lawrence J. Ellison, Sacramento

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
collaborator

Ono Pharmaceutical Co. Ltd

INDUSTRY

lead

Gilead Sciences

INDUSTRY

NCT02626026 - Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA) | Biotech Hunter | Biotech Hunter